Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: Comparison of PROMIS® to ASCQ-MeSM

Health and Quality of Life Outcomes

Volumn 15, Issue 1, 2017, Pages

  Keller, San ^a   Yang, Manshu ^a   Treadwell, Marsha J ^b   Hassell, Kathryn L ^c  

^a AMERICAN INSTITUTES FOR RESEARCH   (United States)

^b CHILDREN S HOSPITAL OAKLAND   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

ASCQ MeSM; Item response theory; Patient reported outcomes; PROMIS ; Validity, Sickle cell disease

Indexed keywords

ADULT; ADULT SICKLE CELL QUALITY OF LIFE MEASUREMENT SYSTEM; ANXIETY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; EMOTIONALITY; FATIGUE; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM; PATIENT SATISFACTION; PHYSICAL PERFORMANCE; PSYCHOMETRY; QUALITY OF LIFE ASSESSMENT; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; SLEEP DISORDER; SOCIAL BEHAVIOR; VALIDITY; WELLBEING; MIDDLE AGED; PAIN; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; STANDARDS; VALIDATION STUDY; YOUNG ADULT;

ADULT; ANEMIA, SICKLE CELL; DEPRESSION; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85020009739     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/s12955-017-0661-5     Document Type: Article

References (100)

1. Claster S, Vichinsky EP. Managing sickle cell disease. BMJ. 2003;327(7424):1151-5.
2. Treadwell MT, et al. Adult sickle cell quality of life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research. Clin J Pain. 2013;30(10):902-14.
3. Keller SD, et al. Patient reports of health outcome for adults living with sickle cell disease: development and testing of ASCQ-Me item banks. Health Qual Life Outcomes. 2014;22:125.
4. N.I.H. Department of Health and Human Services, editor. RFA-CA-13-008: Person-centered outcomes research resource. 2013.
5. Smith A, et al. News from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity. Transl Behav Med. 2016;6(3):470-74.
6. Fries JF, Bruce B, Cella D. The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S53-7.
7. DeWalt DA, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007;45(5 Suppl 1):S12-21.
8. Cella D, et al. The future of outcomes measurement: item banking, tailored short-forms, and computerized adaptive assessment. Qual Life Res. 2007;16 Suppl 1:133-41.
9. Adler D. Developing the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5):S1-2.
10. Aisiku IP, et al. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009;53(5):587-93.
11. Brawley OW, et al. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-8. PMID: 18458271, Epub 2008 May 5.
12. DeBaun MR, Kirkman FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829-38.
13. Quinn CT, et al. Improved survival of children and adolescents with sickle cell disease. Blood. 2010;115(17):3447-52.
14. DeBaun MR, Telfair J. Transition and sickle cell disease. Pediatrics. 2012;130(5):926-35.
15. Halasa NB, et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis. 2007;44(11):1428-33.
16. Yawn BP, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-48.
17. National Heart, Lung and Blood Institute [website]. Workshop on Adults with Sickle Cell Diseases: Meeting Unmet Needs. Executive Summary and Recommendations. Retrieved September 8, 2015, from http://www.nhlbi.nih.gov/meetings/scdmtng/execsum.htm.
18. Badawy SM, et al. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2016 Nov.;28 [Epub ahead of print].
19. Beverung LM, et al. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol. 2015;90(2):139-43.
20. Bhatia M, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant. 2015;21(4):666-72.
21. Kelly MJ, et al. Journeys to recovery study, HSCT-CHESS™ study. Health-related quality of life (HRQL) in children with sickle cell disease and thalassemia following hematopoietic stem cell transplant (HSCT). Pediatr Blood Cancer. 2012;59(4):725-31. Epub 2011 Dec 19.
22. Thornburg CD, et al. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011;33(4):251-4.
23. Bjorner JB, et al. Developing tailored instruments: item banking and computerized adaptive assessment. Qual Life Res. 2007;16 Suppl 1:95-108.
24. Reeve BB, et al. Psychometric evaluation and calibration of health-related quality of life item banks: plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med Care. 2007;45(5 Suppl 1):S22-31.
25. Keller S, Yang M. Development of an "R"-Based Computer Adaptive Assessment of Health Based on Patient Reports of their Functioning and Wellbeing. Poster presented at: The 119th Annual American Psychological Association Convention; Aug 4-7 2011; Washington, D.C.
26. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care. 1989;27(3 Suppl):S217-32.
27. Kantz ME, et al. Methods for assessing condition-specific and generic functional status outcomes after total knee replacement. Med Care. 1992;30(5 Suppl):Ms240-52.
28. Fried TR, et al. Views of older persons with multiple morbidities on competing outcomes and clinical decision-making. J Am Geriatr Soc. 2008;56(10):1839-44.
29. Gliklich RE, Hilinski JM. Longitudinal sensitivity of generic and specific health measures in chronic sinusitis. Qual Life Res. 1995;4(1):27-32.
30. Rothrock NE, et al. Relative to the general US population, chronic diseases are associated with poorer health-related quality of life as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2010;63(11):1195-204.
31. Weaver KE, et al. Mental and physical health-related quality of life among US cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2010;21(11):2108-17.
32. Bessette L, et al. Comparative responsiveness of generic versus disease-specific and weighted versus unweighted health status measures in carpal tunnel syndrome. Med Care. 1998;36(4):491-502.
33. Wong CK, et al. Condition-specific measure was more responsive than generic measure in colorectal cancer: all but social domains. J Clin Epidemiol. 2013;66(5):557-65.
34. Walsh TL, et al. Is a condition-specific instrument for patients with low back pain/leg symptoms really necessary? The responsiveness of the Oswestry Disability Index, MODEMS, and the SF-36. Spine (Phila Pa 1976). 2003;28(6):607-15.
35. Papuga MO, et al. Validation of GAITRite and PROMIS as high-throughput physical function outcome measures following ACL reconstruction. J Orthop Res. 2014;32(6):793-801.
36. TM sickle cell disease module: feasibility. reliability and validity. Pediatr Blood Cancer. 2013;60(8):1338-44.
37. Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine (Phila Pa 1976). 1983;8(2):141-4.
38. Ren XS, et al. The role of generic and disease-specific measures of physical and role functioning in assessing patient outcomes: a longitudinal study. J Ambul Care Manage. 2005;28(2):157-66.
39. US Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support labeling Claims Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed 25 Apr 2017.
40. Guyatt GH, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42(10):773-8.
41. Sprangers MA, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756-68.
42. de Boer AG, et al. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry. 1996;61(1):70-4.
43. Marks GB, Dunn SM, Woolcock AJ. A scale for the measurement of quality of life in adults with asthma. J Clin Epidemiol. 1992;45(5):461-72.
44. Duncan PW, et al. The stroke impact scale version 2.0: evaluation of reliability, validity, and sensitivity to change. Stroke. 1999;30(10):2131-40.
45. Hung M, et al. New paradigm for patient-reported outcomes assessment in foot & ankle research: computerized adaptive testing. Foot Ankle Int. 2012;33(8):621-6.
46. Olino TM, et al. Comparisons across depression assessment instruments in adolescence and young adulthood: an item response theory study using two linking methods. J Abnorm Child Psychol. 2013;41(8):1267-77.
47. Rose M, et al. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient-Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol. 2008;61(1):17-33.
48. Choi SW, et al. Efficiency of static and computer adaptive short forms compared to full-length measures of depressive symptoms. Qual Life Res. 2010;19(1):125-36.
49. Bender MA, Seibel GD. Sickle cell disease. 2003, Sep 15 [updated 2014 Oct23] In: Pagan RA, et al. editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.
50. Steinberg MH. Sickle cell anemia, the first molecular disease: overview of molecular etiology, pathophysiology, and therapeutic approaches. Scientific World J. 2008;25(8):1295-324.
51. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005;129(4):465-81.
52. Sebastiani P, et al. A network model to predict the risk of death in sickle cell disease. Blood. 2007;110(7):2727-35.
53. Akinola NO, et al. The import of abdominal pain in adults with sickle cell disorder. West Afr J Med. 2009;28(2):83-6.
54. Ballas SK, et al. Sickle cell disease: current clinical management. Semin Hematol. 2001;38(4):307-14.
55. Sebastiani P, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol. 2010;85(1):29-35.
56. Steinberg MH, Adewoye AH. Modifier genes and sickle cell anemia. Curr Opin Hematol. 2006;13(3):131-6.
57. Mayer ML, et al. Hospital resource utilization among patients with sickle cell disease. J Health Care Poor Underserved. 2003;14(1):122-35.
58. Loureiro MM, et al. Factors associated with hospital readmission in sickle cell disease. BMC Blood Disord. 2009;9:2. doi: 10.1186/1471-2326-9-2.
59. Dabari S, et al. Severe painful vaso-occlusive crises and mortality in contemporary adult sickle cell anemia cohort study. PLoS One. 2013;8(11):e79923.
60. Audard V, et al. Acute kidney injury in sickle patients with painful crisis or acute chest syndrome and its relation to pulmonary hypertension. Nephrol Dial Transplant. 2010;25(8):2524-9.
61. Frei-Jones MJ, et al. Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer. 2009;52(4):481-5.
62. Carroll CP, et al. The course and correlates of high hospital utilization in sickle cell disease: evidence from a large, urban Medicaid managed care organization. Am J Hematol. 2009;84(10):666-70.
63. Smith WR, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008;148(2):94-101.
64. Dampier C, et al. Vaso-occlusion in children with sickle cell disease: clinical characteristics and biologic correlates. J Pediatr Hematol Oncol. 2004;26(12):785-90.
65. Vick LR, et al. Partial splenectomy prevents splenic sequestration crises in sickle cell disease. J Pediatr Surg. 2009;44(11):2088-91.
66. Halabi-Tawil M. Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. Br J Dermatol. 2008;158(2):339-44.
67. Nolan VG, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol. 2006;133(5):570-8.
68. Klings ES, et al. Abnormal pulmonary function in adults with sickle cell anemia. Am J Respir Crit Care Med. 2006;173(11):1264-9.
69. Gill FM, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood. 1995;86(2):776-83.
70. Cheng L, et al. Health related quality of life in pregeriatric patients with chronic diseases at urban, public supported clinics. Health Qual Life Outcomes. 2003;1:63.
71. Wensing M, et al. Functional status, health problems, age and comorbidity in primary care patients. Qual Life Res. 2001;10(2):141-8.
72. Michelson H, et al. Multiple chronic health problems are negatively associated with health related quality of life (HRQoL) irrespective of age. Qual Life Res. 2000;9(10):1093-104.
73. Meyer HH. Methods for scoring a check-list type rating scale. J Appl Psychol. 1951;35(1):46-9.
74. Bland AC, et al. The psychometric properties of five scoring methods applied to the script concordance test. Acad Med. 2005;80(4):395-9.
75. Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-83.
76. Hays RD, et al. The RAND 36-Item Health Survey 1.0. Health Econ. 1993;2(3):217-27.
77. Jones N, et al. The Medicare Health Outcomes Survey program: overview, context, and near-term prospects. Health Qual Life Outcomes. 2004;2:33.
78. Dampier C, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203-5.
79. Levenson JL, et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med. 2008;70(2):192-6.
80. Liu H, et al. Representativeness of the patient-reported outcomes measurement information system internet panel. J Clin Epidemiol. 2010;63(11):1169-78.
81. Cella D, et al. Initial item banks and first wave testing of the Patient-Reported Outcomes Measurement Information System (PROMIS) network: 2005-2008. J Clin Epidemiol. 2010;63(11):1169-94.
82. Cronbach L. Coefficient alpha and the internal structure of tests. Psychometrika. 1951;16(3):297-334.
83. Abdi H. Bonferroni and Šidák corrections for multiple comparisons, in encyclopedia of measurement and statistics. Thousand Oaks: Sage; 2007.
84. Liang MH, et al. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum. 1985;28(5):542-7.
85. Keller SD, et al. The SF-36 Arthritis-Specific Health Index (ASHI): II. Tests of validity in four clinical trials. Med Care. 1999;37(5 Suppl):MS51-60.
86. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Routledge; 1988.
87. Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill Book Company; 1967.
88. Streiner DL. Starting at the beginning: an introduction to coefficient alpha and internal consistency. J Pers Assess. 2003;80(1):99-103.
89. Kaplan RM, Saccuzzo DP. Pscyhological testing: principles, applications and issues. Eighth ed. Belmont: Wasdworth, Cengage Learning; 2013.
90. Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw-Hill; 1994.
91. Vichinsky E, et al. Neuropsychological dysfunction and neuroimaging adult sickle cell anemia study group. Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA. 2010;303(18):1823-31.
92. Ballas SK, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World J. 2012. Published online 2012 Aug 1.
93. Tulsky DS, et al. Methodology for the development and calibration of the SCI-QOL item banks. J Spinal Cord Med. 2015;38(3):270-87.
94. Keller S, Yang M. Disease-specific calibrations or disease-specific content: which is responsible for the enhanced sensitivity of condition-specific measures compared to generic measures? Qual Life Res. 2015;24:25.
95. Centers for Disease Control and Prevention. Registry and Surveillance System for Hemoglobinopathies Pilot Project (RuSH). Available from: http://www.cdc.gov/ncbddd/sicklecell/freematerials.html.
96. Feliu MH, et al. Neurocognitive testing and functioning in adults sickle cell disease. Hemoglobin. 2011;35(5-6):476-84.
97. Cook KF, et al. A PROMIS fatigue short form for use by individuals who have multiple sclerosis. Qual Life Res. 2012;21(6):1021-30.
98. Kratz AL, et al. The PROMIS FatigueFM Profile: a self-report measure of fatigue for use in fibromyalgia. Qual Life Res. 2016;25:1803.
99. Choi SW. Firestar: computerized adaptive testing simulation program for polytomous item response theory models. Appl Psychol Measur. 2009;33(8):644.
100. Jaeschke R, et al. Measurement of health status: ascertaining the minimally clinically important difference. Cont Clin Trials. 1989;10:407-15.